Clinical trials and epidemiological studies have suggested that cyclooxygenase 2 (COX2) is involved in colorectal cancer development and its inhibition can reduce the risk of cancer in general and more specifically of colorectal cancer [3–7]. This evidence concerns the gene PTGS2 and cancer.